maybe why its going down.
See it Market
This Week In IPOs: “Risk-Off”, Boutique Investment Banking And Sickle Cell Disease
August 10, 2015 Investing Research
( GBT )
GBT is developing the initial product candidate, GBT440, as a once-daily, oral prophylactic therapy for sickle cell disease.GBT plans to explore the treatment of more indications, notably hypoxemic pulmonary disorders and hereditary angioedema.
Highlights. Sickle Cell Disease ,Severe disease with major unmet medical need, large market opportunity. Highly experience team with successful track record in developing and commercializing drugs. Co. has contributed to 18 drug approvals
great buy opportunity
August 1, 2015
Synergy Pharmaceuticals (SGYP) Stock Is Headed For Massive Gains
I’ve got overwhelmingly bullish expectations for Synergy Pharmaceuticals stock. The reality is that the plecanatide study went incredibly well; and following the strong phase 3b results, the company is planning on an NDA submission in the near future. In the world of biotech, these types of things tend to be catalysts that lead to strong growth in the stock the events are represented by. It would also make sense for an acquisition to take place. So, we’ll want to keep an eye out for any developments there as a buyout offer would likely send Synergy Pharmaceuticals soaring in the market. Nonetheless, whether or not a buyout happens, I’m expecting to see strong growth in the long run. Synergy is likely to represent incredibly profitable buying opportunities
Bloomberg reported after last Phase III Data- SGYP Discussing Buyout w/ Avisors LINK
The Fly On The Wall or Google It
see u there
What to Expect from Exelixis (EXEL) This Earnings Season?
Yahoo Finance - 1 day ago
The company has an impressive track record, having beat estimates comfortably in the last four quarters
good link from Barron's-Trek Trader Daily By: Tiernan Ray
Sentiment: Strong Buy
Booming growth plus new international growth- monster money maker here.